Perinatal vs Genetic Programming of Serotonin States Associated with Anxiety

Neuropsychopharmacology

Volumn 40, Issue 6, 2015, Pages 1456-1470

  Altieri, Stefanie C ^a,b   Yang, Hongyan ^a   O'Brien, Hannah J ^a   Redwine, Hannah M ^c   Senturk, Damla ^d   Hensler, Julie G ^c   Andrews, Anne M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SLC6A4 PROTEIN, MOUSE;

129 MOUSE; ANIMAL; ANXIETY DISORDERS; BRAIN; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; KNOCKOUT MOUSE; MALE; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; BRAIN; CITALOPRAM; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FEMALE; FLUOXETINE; MALE; MICE, 129 STRAIN; MICE, KNOCKOUT; MOTOR ACTIVITY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION;

EID: 84939787582     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.331     Document Type: Article

References (84)

1. Altieri S, Singh Y, Sibille E, Andrews A (2012). Serotonergic pathways in depression. In: Lopez-Munoz F, Alamo C (eds). Neurobiology of Depression. CRC Press, Taylor & Francis Group: Boca Raton, FL, USA, pp 143-170.
2. Altieri SC, Garcia-Garcia AL, Leonardo ED, Andrews AM (2013). Rethinking 5-HT(1A) receptors: emerging modes of inhibitory feedback of relevance to emotion-related behavior. ACS Chem Neurosci 4: 72-83.
3. Ansorge MS, Morelli E, Gingrich JA (2008). Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci 28: 199-207.
4. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA (2004). Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306: 879-881.
5. Beikmann BS, Tomlinson ID, Rosenthal SJ, Andrews AM (2013). Serotonin uptake is largely mediated by platelets versus lymphocytes in peripheral blood cells. ACS Chem Neurosci 4: 161-170.
6. Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A et al (1998). Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ('Ecstasy') in serotonin transporter-deficient mice. Mol Pharmacol 53: 649-655.
7. Borsini F, Lecci A, Sessarego A, Frassine R, Meli A (1989). Discovery of antidepressant activity by forced swimming test may depend on pre-exposure of rats to a stressful situation. Psychopharmacology (Berl) 97: 183-188.
8. Brand SR, Brennan PA (2009). Impact of antenatal and postpartum maternal mental illness: how are the children? Clin Obstet Gynecol 52: 441-455.
9. Brigman JL, Mathur P, Lu L, Williams RW, Holmes A (2009). Genetic relationship between anxiety-related and fear-related behaviors in BXD recombinant inbred mice. Behav Pharmacol 20: 204-209.
10. Burke TF, Advani T, Adachi M, Monteggia LM, Hensler JG (2013). Sensitivity of hippocampal 5-HT1A receptors to mild stress in BDNF-deficient mice. Int J Neuropsychopharmacol 16: 631-645.
11. Cahir M, Ardis T, Reynolds GP, Cooper SJ (2007). Acute and chronic tryptophan depletion differentially regulate central 5-HT1A and 5-HT2A receptor binding in the rat. Psychopharmacology (Berl) 190: 497-506.
12. Carrasco JL, Sandner C (2005). Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract 59: 1428-1434.
13. Carroll JC, Boyce-Rustay JM, Millstein R, Yang R, Wiedholz LM, Murphy DL et al (2007). Effects of mild early life stress on abnormal emotion-related behaviors in 5-HTT knockout mice. Behav Genet 37: 214-222.
14. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A et al (2003). Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 142: 402-408.
15. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE (2010). Genetic sensitivity to the environment: The case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 167: 509-527.
16. Clancy B, Kersh B, Hyde J, Darlington RB, Anand KJ, Finlay BL (2007). Web-based method for translating neurodevelopment from laboratory species to humans. Neuroinformatics 5: 79-94.
17. Cryan JF, O'Leary OF, Jin SH, Friedland JC, Ouyang M, Hirsch BR et al (2004). Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc Natl Acad Sci USA 101: 8186-8191.
18. Daws LC, Munn JL, Valdez MF, Frosto-Burke T, Hensler JG (2007). Serotonin transporter function, but not expression, is dependent on brain-derived neurotrophic factor (BDNF): In vivo studies in BDNF-deficient mice. J Neurochem 101: 641-651.
19. Descarries L, Riad M (2012). Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT1A receptors and SERT. Philos Trans R Soc Lond B Biol Sci 367: 2416-2425.
20. Fraser LM, Brown RE, Hussin A, Fontana M, Whittaker A, O'Leary TP et al (2010). Measuring anxiety- and locomotion-related behaviours in mice: a new way of using old tests. Psychopharmacology 211: 99-112.
21. Gross C, Santarelli L, Brunner D, Zhuang X, Hen R (2000). Altered fear circuits in 5-HT(1A) receptor KO mice. Biol Psychiatry 48: 1157-1163.
22. Guilloux JP, Seney M, Edgar N, Sibille E (2011). Integrated behavioral z-scoring increases the sensitivity and reliability of behavioral phenotyping in mice: relevance to emotionality and sex. J Neurosci Methods 197: 21-31.
23. Hensler JG (2002). Differential regulation of 5-HT1A receptor-G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacology 26: 565-573.
24. Hjorth S, Auerbach SB (1994). Further evidence for the importance of 5-HT1A autoreceptors in the action of selective serotonin reuptake inhibitors. Eur J Pharmacol 260: 251-255.
25. Hjorth S, Westlin D, Bengtsson HJ (1997). WAY100635-induced augmentation of the 5-HT-elevating action of citalopram: Relative importance of the dose of the 5-HT1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor. Neuropharmacology 36: 461-465.
26. Holmes A, Li Q, Murphy DL, Gold E, Crawley JN (2003a). Abnormal anxiety-related behavior in serotonin transporter null mutant mice: The influence of genetic background. Genes Brain Behav 2: 365-380.
27. Holmes A, Rodgers RJ (1998). Responses of Swiss-Webster mice to repeated plus-maze experience: Further evidence for a qualitative shift in emotional state? Pharmacol Biochem Behav 60: 473-488.
28. Holmes A, Yang RJ, Lesch K-P, Crawley JN, Murphy DL (2003b). Mice lacking the serotonin transporter exhibit 5-HT(1A) receptor-mediated abnormalities in tests for anxiety-like behavior. Neuropsychopharmacology 28: 2077-2088.
29. Homberg JR, Olivier JD, Smits BM, Mul JD, Mudde J, Verheul M et al (2007). Characterization of the serotonin transporter knockout rat: a selective change in the functioning of the serotonergic system. Neuroscience 146: 1662-1676.
30. Homberg JR, Schubert D, Gaspar P (2010). New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 31: 60-65.
31. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD et al (2006). Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78: 815-826.
32. Jennings KA, Loder MK, Sheward WJ, Pei Q, Deacon RM, Benson MA et al (2006). Increased expression of the 5-HT transporter confers a low-anxiety phenotype linked to decreased 5-HT transmission. J Neurosci 26: 8955-8964.
33. Joeyen-Waldorf J, Edgar N, Sibille E (2009). The roles of sex and serotonin transporter levels in age- and stress-related emotionality in mice. Brain Res 1286: 84-93.
34. Kalueff AV, Gallagher PS, Murphy DL (2006). Are serotonin transporter knockout mice 'depressed'? Hypoactivity but no anhedonia. Neuroreport 17: 1347-1351.
35. Kalueff AV, Jensen CL, Murphy DL (2007). Locomotory patterns, spatiotemporal organization of exploration and spatial memory in serotonin transporter knockout mice. Brain Res 1169: 87-97.
36. Karpova NN, Lindholm J, Pruunsild P, Timmusk T, Castren E (2009). Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. Eur Neuropsychopharmacol 19: 97-108.
37. Lapiz-Bluhm MD, Bondi CO, Doyen J, Rodriguez GA, Bedard-Arana T, Morilak DA (2008). Behavioural assays to model cognitive and affective dimensions of depression and anxiety in rats. J Neuroendocrinol 20: 1115-1137.
38. Leuchter AF, Cook IA, Hamilton SP, Narr KL, Toga A, Hunter AM et al (2010). Biomarkers to predict antidepressant response. Curr Psychiatry Rep 12: 553-562.
39. Li Q, Wichems C, Heils A, Lesch KP, Murphy DL (2000). Reduction in the density and expression, but not G-protein coupling, of serotonin receptors (5-HT1A) in 5-HT transporter knock-out mice: gender and brain region differences. J Neurosci 20: 7888-7895.
40. Li Q, Wichems C, Heils A, Van De Kar LD, Lesch KP, Murphy DL (1999). Reduction of 5-hydroxytryptamine (5-HT)(1A)-mediated temperature and neuroendocrine responses and 5-HT(1A) binding sites in 5-HT transporter knockout mice. J Pharmacol Exp Ther 291: 999-1007.
41. Licht CL, Kirkegaard L, Zueger M, Chourbaji S, Gass P, Aznar S et al (2010). Changes in 5-HT4 receptor and 5-HT transporter binding in olfactory bulbectomized and glucocorticoid receptor heterozygous mice. Neurochem Int 56: 603-610.
42. Lindsley CW (2012). The top prescription drugs of 2011 in the United States: antipsychotics and antidepressants once again lead CNS therapeutics. ACS Chem Neurosci 3: 630-631.
43. Lucki I (1997). The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8: 523-532.
44. Luellen BA, Bianco LE, Schneider LM, Andrews AM (2007). Reduced brain-derived neurotrophic factor is associated with a loss of serotonergic innervation in the hippocampus of aging mice. Genes Brain Behav 6: 482-490.
45. Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RCS et al (2006). Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 31: 47-57.
46. Martin KF, Phillips I, Hearson M, Prow MR, Heal DJ (1992). Characterization of 8-OH-DPAT-induced hypothermia in mice as a 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants. Br J Pharmacol 107: 15-21.
47. Mathews TA, Fedele DE, Coppelli FM, Avila AM, Murphy DL, Andrews AM (2004). Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J Neurosci Methods 140: 169-181.
48. McQuade R, Sharp T (1997). Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis. J Neurochem 69: 791-796.
49. Mirmiran M, van de Poll NE, Corner MA, van Oyen HG, Bour HL (1981). Suppression of active sleep by chronic treatment with chlorimipramine during early postnatal development: effects upon adult sleep and behavior in the rat. Brain Res 204: 129-146.
50. Misri S, Reebye P, Kendrick K, Carter D, Ryan D, Grunau RE et al (2006). Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry 163: 1026-1032.
51. Mitchell C, Notterman D, Brooks-Gunn J, Hobcraft J, Garfinkel I, Jaeger K et al (2011). Role of mother's genes and environment in postpartum depression. Proc Natl Acad Sci USA 108: 8189-8193.
52. Murphy DL, Fox MA, Timpano KR, Moya PR, Ren-Patterson R, Andrews AM et al (2008a). How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology 55: 932-960.
53. Murphy DL, Lesch K-P (2008b). Targeting the murine serotonin transporter: insights into human neurobiology. Nat Rev Neurosci 9: 85-96.
54. Murphy DL, Maile MS, Vogt NM (2013). 5HTTLPR: white knight or dark blight? ACS Chem Neurosci 4: 13-15.
55. Murphy DL, Moya PR (2011). Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional GxG and GxE differences in health and disease. Curr Opin Pharmacol 11: 3-10.
56. Nordeng H, Lindemann R, Perminov KV, Reikvam A (2001). Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 90: 288-291.
57. Oberlander TF, Gingrich JA, Ansorge MS (2009). Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther 86: 672-677.
58. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C (2006). Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 63: 898-906.
59. Olivier JD, Van Der Hart MG, Van Swelm RP, Dederen PJ, Homberg JR, Cremers T et al (2008). A study in male and female 5-HT transporter knockout rats: an animal model for anxiety and depression disorders. Neuroscience 152: 573-584.
60. Paxinos G, Franklin KBJ (2001). The Mouse Brain in Stereotaxic Coordinates. 2nd edn. Academic Press: New York, NY, USA.
61. Perez XA, Andrews AM (2005). Chronoamperometry to determine differential reductions in uptake in brain synaptosomes from serotonin transporter knockout mice. Anal Chem 77: 818-826.
62. Popa D, Cerdan J, Repérant C, Guiard BP, Guilloux J-P, David DJ et al (2010). A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain. Eur J Pharmacol 628: 83-90.
63. Popa D, Lena C, Alexandre C, Adrien J (2008). Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: evidence from sleep, stress, and behavior. J Neurosci 28: 3546-3554.
64. Porsolt RD, Brossard G, Hautbois C, Roux S (2001). Rodent models of depression: forced swimming and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci Chapter 8: Unit 8.10A.
65. Porsolt RD, Le Pichon M, Jalfre M (1977). Depression: a new animal model sensitive to antidepressant treatments. Nature 266: 730-732.
66. Richardson-Jones JW, Craige CP, Guiard BP, Stephen A, Metzger KL, Kung HF et al (2010). 5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron 65: 40-52.
67. Richardson-Jones JW, Craige CP, Nguyen TH, Kung HF, Gardier AM, Dranovsky A et al (2011). Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. J Neurosci 31: 6008-6018.
68. Richer M, Hen R, Blier P (2002). Modification of serotonin neuron properties in mice lacking 5-HT1A receptors. Eur J Pharmacol 435: 195-203.
69. Rossi DV, Burke TF, Hensler JG (2008a). Differential regulation of serotonin-1A receptor-stimulated [35S]GTP gamma S binding in the dorsal raphe nucleus by citalopram and escitalopram Eur J Pharmacol 583: 103-107.
70. Rossi DV, Burke TF, McCasland M, Hensler JG (2008b). Serotonin-1A receptor function in the dorsal raphe nucleus following chronic administration of the selective serotonin reuptake inhibitor sertraline. J Neurochem 105: 1091-1099.
71. Shen Q, Lal R, Luellen BA, Earnheart JC, Andrews AM, Luscher B (2010). Gamma-Aminobutyric acid-type A receptor deficits cause hypothalamic-pituitary-adrenal axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression. Biol Psychiatry 68: 512-520.
72. Sibille E, Lewis DA (2006). SERT-ainly involved in depression, but when? Am J Psychiatry 163: 8-11.
73. Sinton CM, Fallon SL (1988). Electrophysiological evidence for a functional differentiation between subtypes of the 5-HT1 receptor. Eur J Pharmacol 157: 173-181.
74. Suri R, Stowe ZN, Hendrick V, Hostetter A, Widawski M, Altshuler LL (2002). Estimates of nursing infant daily dose of fluoxetine through breast milk. Biol Psychiatry 52: 446-451.
75. Szapacs M, Mathews T, Tessarollo L, Lyons WE, Andrews A (2004). Exploring the relationship between serotonin and brain-derived neurotrophic factor: analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression. J Neurosci Methods 140: 81-92.
76. Tao R, Ma Z, Auerbach SB (2000). Differential effect of local infusion of serotonin reuptake inhibitors in the raphe versus forebrain and the role of depolarization-induced release in increased extracellular serotonin. J Pharmacol Exp Ther 294: 571-579.
77. Tjurmina OA, Armando I, Saavedra JM, Goldstein DS, Murphy DL (2002). Exaggerated adrenomedullary response to immobilization in mice with targeted disruption of the serotonin transporter gene. Endocrinology 143: 4520-4526.
78. Vogel G, Neill D, Hagler M, Kors D (1990). A new animal model of endogenous depression: a summary of present findings. Neurosci Biobehav Rev 14: 85-91.
79. Walf AA, Frye CA (2007). The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2: 322-328.
80. Wenthur CJ, Bennett MR, Lindsley CW (2014). Classics in chemical neuroscience: fluoxetine (Prozac). ACS Chem Neurosci 5: 14-23.
81. Workman AD, Charvet CJ, Clancy B, Darlington RB, Finlay BL (2013). Modeling transformations of neurodevelopmental sequences across mammalian species. J Neurosci 33: 7368-7383.
82. Yang H, Thompson AB, McIntosh BJ, Altieri SC, Andrews AM (2013). Physiologically relevant changes in serotonin resolved by fast microdialysis. ACS Chem Neurosci 4: 790-798.
83. Yu Q, Teixeira CM, Mahadevia D, Huang Y, Balsam D, Mann JJ et al (2014). Dopamine and serotonin signaling during two sensitive developmental periods differentially impact adult aggressive and affective behaviors in mice. Mol Psychiatry. 19: 688-698.
84. Zhong H, Haddjeri N, Sanchez C (2012). Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter - a review of current understanding of its mechanism of action. Psychopharmacology 219: 1-13.